New Path Molecular is delighted to announce the closing of a pre-seed round to fund the proof of concept for our phosphatidylserine targeting cancer therapy. The round was lead by previous investors Deepbridge Capital. The team are delighted to be pushing forward this project which was started in collaboration with the late Prof Michael Wakelham.